Transient neonatal hyperthyroidism and maternal thyroid stimulating immunoglobulins T MATSUDA,* T MOMOI,* K AKAISHI,* T YAGURA,t K KASAGI,t AND K ENDOt Departments of *Paediatrics and tEndocrinology, Tenri Hospital, Tenri, Nara, and *Department of Nuclear Medicine, Kyoto University Faculty of Medicine, Sakyo-ku, Kyoto, Japan SUMMARY Serum thyroid stimulating hormone binding inhibitor immunoglobulins (TBII) and thyroid stimulating antibody (TSAb) concentrations were measured in three pregnant women with hyperthyroidism and then in their infants. The results suggested that TBII concentrations in infants in the neonatal period or from mothers during the third trimester of pregnancy showed a good correlation with the development of neonatal hyperthyroidism.
It is now widely believed that the transient thyroid overactivity in infants born to mothers with hyperthyroidism is a result of the placental transfer of thyroid stimulating immunoglobulins from the mother to the infant. The immunoglobulins in the sera from some patients with Graves' disease were shown, by the radioreceptor assay system, to inhibit the binding of thyroid stimulating hormone to its receptor sites and were designated as thyroid stimulating hormone binding inhibitor immunoglobulins (TBII).1 It was also shown that immunoglobulins in the patient's sera stimulated the production of cyclic AMP in human thyroid tissues and were known as thyroid stimulating antibodies (TSAb). 2 We studied three unrelated infants who were born to women with hyperthyroidism, and one of them developed typical transient neonatal hyperthyroidism. We measured serum TBII and TSAb concentrations in these infants and their mothers.
Case reports Family 1 The mother developed hyperthyroidism at 26 years old when she was in her 32nd week of pregnancy. From the 34th week until delivery she had been maintained euthyroid with methimazole. A girl (3330 g) was born at 39 weeks' gestation. On the 8th day of life she was noted to be hyperactive and had developed diarrhoea. Tachycardia was noticed on the 10th day when her body weight was 3100 g. Thyroid studies on day 8 showed that she had hyperthyroidism; she had serum concentrations of triiodothyronine, thyroxine, free thyroxine, and thyroid stimulating hormone of 8-6 nmol/l, 527 6 nmol/l, 350-8 pmol/l, and <10 mU/l, respectively. Treatment with propylthiouracyl and Lugol's solution was started on day 13. Her condition and thyroid function improved gradually and the treatments were stopped on day 59. Her physical and mental development and the thyroid function tests gave normal results at 10 months of age.
Family 2 The mother was first diagnosed as having hyperthyroidism at 29 years old. Two years after the diagnosis she received partial thyroidectomy because of a poor response to antithyroid drugs. After the surgery she had been maintained euthyroid with thyroxine supplement. A girl was born at 39 weeks' gestation. Her development and thyroid function were normal during 10 months of follow up.
Family 3 The mother developed hyperthyroidism at 22 years old when she was four months pregnant. Treatment was started with methimazole but she remained hyperthyroid during the rest of her pregnancy. A boy (2590 g) was born at 39 weeks' gestation and his thyroid function, detected in the cord blood, was normal. Thyroid hormone concentrations gradually decreased until 2 weeks of age when serum concentrations of triiodothyronine, thyroxine, and free thyroxine were 1-3 nmol/l, 47-7 nmol, and 8-0 pmolVl, respectively. The hormone concentrations returned to the normal ranges at 1.5 months of age without treatment. Throughout this period thyroxine binding globulin concentrations were normal and thyroid stimulating hormone concentrations were always less than 1-0 mU/l. At 4 months of age his development and thyroid functions were normal.
Methods
Serum samples from the three pregnant women and their infants were stored at -20°C until assayed.
During follow up some of the specimens taken at certain intervals from the same infant were combined for TBII and TSAb assays.
Serum TBII was assayed by the method of Shewring and Smith3 using a commercial kit (Japan Travenol, Japan). Serum TSAb concentrations were assayed by the method of Kasagi et al.4
Results
In the infant in family 1 who developed neonatal hyperthyroidism, both TBII and TSAb concentrations were high at birth ( 
